BRAF and melanoma: We performed RNA-seq on EGFR-mutant PC9 NSCLC cells treated with the EGFR inhibitor gefitinib and BRAF-mutant SKMEL28 melanoma cells treated with the BRAF inhibitor dabrafenib to investigate the scope of the transcriptional changes in each system and to uncover shared mechanisms of drug tolerance.